<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066157</url>
  </required_header>
  <id_info>
    <org_study_id>IA0048</org_study_id>
    <secondary_id>R01AG017196-03</secondary_id>
    <secondary_id>FDA IRB approval M1285</secondary_id>
    <secondary_id>NIH grant AG17196-03</secondary_id>
    <nct_id>NCT00066157</nct_id>
  </id_info>
  <brief_title>Alzheimer's Disease: Therapeutic Potential of Estrogen</brief_title>
  <official_title>Alzheimer's Disease: Therapeutic Potential of Estrogen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 15-month study to determine the effectiveness of hormone replacement therapy in
      improving memory and the ability to live independently in postmenopausal women with
      Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogen is a naturally occurring hormone produced in a woman's body. The purpose of this
      15-month study is to determine the effectiveness of hormone replacement therapy in improving
      memory and the ability to live independently in postmenopausal women with Alzheimer's disease
      and without other dementias.

      Patients who volunteer for this study will either receive a patch containing 17-ß-estradiol
      or will receive an inactive placebo patch. In addition, patients will be given either
      medroxyprogesterone or an inactive placebo pill. Neither the volunteers nor the study staff
      will know which type of patch or pill a patient receives. Patients must be generally healthy
      and have mild-to-moderate dementia. There must be a patient caregiver who can watch for side
      effects and ensure that the patient takes the study medications on schedule. Patients will
      undergo neuropsychological tests and an evaluation of the ability to live independently at
      each visit as well as laboratory evaluations, such as the taking of blood. Each visit will
      last approximately 3 hours. A total of 160 participants are being recruited.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition: delayed recall on Buschke Selective Reminding Test; Stroop Interference condition--completion time and errors; Clinician-rated Interview Based Impression of Change</measure>
    <time_frame>Baseline and 1, 3, 6, 12, and 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skills of Independent Living: Physical functioning Performance (PFP)</measure>
    <time_frame>Baseline and 1, 3, 6, 12, and 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioassays (Estradiol, estrone, medroxyprogesterone, FSH, influence of ApoE genotype in responsivity to estrogen)</measure>
    <time_frame>Baseline and 1, 3, 6, 12, and 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>estradiol patch and medroxyprogesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>estradiol patch and placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo patch and medroxyprogesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo patch and placebo pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal estradiol</intervention_name>
    <description>50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>17 (beta) estradiol transdermal patch</other_name>
    <other_name>Estrogen replacement therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone</intervention_name>
    <description>2.5mg tablet daily for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>Transdermal placebo patch, changed every 3 days, for 12 months</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet daily for 12 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed
             by study staff or from an outside clinic)

          -  Mini Mental State Examination score greater than 15/30

        Exclusion Criteria:

          -  History of cancer of reproductive tissues

          -  History of deep vein thrombosis or blot clots

          -  Diabetes

          -  Heart disease or stroke

          -  Liver problems including hepatitis

          -  Severe vision or hearing problems

          -  Tobacco use

          -  Lack of an adequate caregiver

          -  inability to perform psychometric testing
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Asthana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin - Madison, William S. Middleton VA Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Memory Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging. 2002;19(6):405-27. Review.</citation>
    <PMID>12149049</PMID>
  </reference>
  <reference>
    <citation>Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001 Aug 28;57(4):605-12.</citation>
    <PMID>11524467</PMID>
  </reference>
  <reference>
    <citation>Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999 Aug;24(6):657-77.</citation>
    <PMID>10399774</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2003</study_first_submitted>
  <study_first_submitted_qc>August 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2003</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer disease</keyword>
  <keyword>Hormone replacement therapy</keyword>
  <keyword>Postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

